Canada Regulatory Update
Health Canada has accepted for review the New Drug Submission for AMX0035 (or PB-TURSO*) for the treatment of ALS.
*Abbreviation: PB-TURSO, sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine)
Every Moment Matters
At Amylyx our moments are spent in the pursuit of furthering treatment for those living with neurodegenerative diseases. Every day presents an opportunity to turn these rapidly progressing diseases into conditions that can be managed medically, and effectively. With the end goal of giving people more quality time with the ones they love.
SIGN UP FOR LATEST NEWS & UPDATES
What Drives Us
Amylyx represents hope for the community and hope is everything. Hope is why you get through today and wake up tomorrow ready to go.”
— Nadia, an ALS wife & caregiver
I feel like Amylyx is a very different company than most that I work with and truly seems like a company that cares, with a big heart, but further than that is you have a fierceness in you and you’re not going to back down from so many of the obstacles that ALS patients have been facing.”
— Sandy, a person living with ALS
Grow With Us
We believe in the power of the individual, the strength of personal connection, and the passion of humanity to address the effects of neurodegenerative diseases. Amylyx was built on the foundation of audacious curiosity, relentless drive, and meaningful relationships. If that sounds like you, we’d love to talk.
Open Positions
Educational Resources
Our ongoing commitment to people affected by neurodegenerative diseases carries with it a responsibility to be transparent, set realistic expectations, and regularly share updates with patients. Learn about our unique approach, clinical trials, and more.
Mechanism of Disease About AMX0035